Qelbree was Supernus Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $304.65M of $718.95M (42%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trokendi Xr | $261.22M | $94.34M | $63.20M | $42.42M | ||||||
| Qelbree | $61.32M | $140.19M | $241.27M | $304.65M | ||||||
| Gocovri | $104.42M | $119.64M | $130.82M | $146.82M | ||||||
| Oxtellar Xr | $115.35M | $113.40M | $99.46M | $40.70M | ||||||
| Apokyn | $75.31M | $75.08M | $73.93M | $47.77M | ||||||
| Collaboration Revenue (Zurzuvae) | — | — | — | $53.00M | ||||||
| Royalty, Licensing, & Other Revenues | — | $33.59M | $24.12M | $39.42M | ||||||
| Royalty, Licensing & Other Revenues | $17.81M | — | — | — | ||||||
| Other | $31.82M | $31.28M | $29.01M | $26.91M | ||||||
| Onapgo | — | — | — | $17.25M | ||||||
| Royalty & Licensing Revenues | — | — | — | — | ||||||
| Royalty Revenues | — | — | — | — | ||||||
| Royalty Revenue | — | — | — | — | ||||||
| Royalty | — | — | — | — | ||||||
| Licensing Revenue | — | — | — | — | ||||||
| Licensing | — | — | — | — | ||||||
| Total | $667.24M | $607.52M | $661.82M | $718.95M |
Supernus Pharmaceuticals brought in $718.95M from its nine product and service lines in fiscal 2025, the year ended December 31, 2025. Supernus Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $661.82M. Qelbree was the largest at $304.65M (42.4%), ahead of Gocovri at $146.82M (20.4%) and Collaboration Revenue (Zurzuvae) at $53.00M (7.4%). The other six lines brought in $214.48M combined.
Compared with fiscal 2024, Royalty, Licensing, & Other Revenues grew fastest, up 63.4% to $39.42M, while Oxtellar Xr fell the most, down 59.1% to $40.70M.
Supernus Pharmaceuticals began breaking out Collaboration Revenue (Zurzuvae) in fiscal 2025, Royalty, Licensing, & Other Revenues in fiscal 2023 and Onapgo in fiscal 2025. Supernus Pharmaceuticals stopped reporting Royalty, Licensing & Other Revenues as a separate line after fiscal 2022, when it brought in $17.81M.
Supernus Pharmaceuticals (SUPN) reports its revenue by product and service. In fiscal 2025, Qelbree was its largest product and service line, bringing in $304.65M (42.4% of the total), followed by Gocovri at $146.82M (20.4%).
Qelbree was Supernus Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $304.65M, or 42.4% of the $718.95M total across its nine product and service lines.
Every figure comes from Supernus Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Supernus Pharmaceuticals gives it, and years follow its fiscal calendar.
Supernus Pharmaceuticals' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.